CatSci shortlisted for the 2020 BioNow Export award
21 January 2021 - Cardiff, UK
CatSci is pleased to announce that we have been shortlisted for the 2020 BioNow Export award. We are thrilled that the hard work of our team is being recognised as we grow the capacity of the company to meet our customers’ needs and expectations whilst maintaining an exceptional quality of service.
Learn more
COVID-19 Business Update as of 18th January 2021 – We’re here to help you stay on track
18 January 2021 - Cardiff, UK
We would like to reassure all our small molecule innovator partners of some of our measures in place to continue safely enabling the progression of your drug development projects. A number of contingency measures have been implemented to mitigate both the probability and impact of a COVID-19 outbreak disrupting our ability to continue to provide you with vital tailored chemistry services.
Learn more
CatSci further strengthens its customer-focused Strategic Advisory Board with three key appointments
11 November 2020 - Cardiff, UK
Cardiff, UK - CatSci, a scientifically led, commercially minded and award-winning innovation partner, has appointed three key industry thought leaders to its Strategic Advisory Board (SAB), Dr Rob Harris, Kate Smith and Dr Robert Dennehy.
Learn more
CatSci partners with three leading UK organisations to offer expert support across the pharmaceutical supply chain
21 October 2020 - Cardiff, UK
CatSci Ltd today announced partnerships with three UK companies across the pharmaceutical supply chain – M2M Pharmaceuticals (M2M Pharma), New Path Molecular (NPM) and Upperton Pharma Solutions (Upperton). This will provide CatSci’s customers with access to specialised capabilities and expertise, ensuring they can develop affordable, best-in-class small molecule therapeutics that meet their evolving healthcare needs.
Learn more